CIBULA, David, Lukáš DOSTÁLEK, Jiří JARKOVSKÝ, Constantijne H MOM, Aldo LOPEZ, Henrik FALCONER, Giovanni SCAMBIA, Ali AYHAN, Sarah H KIM, David Isla ORTIZ, Jaroslav KLAT, Andreas OBERMAIR, Giampaolo Di MARTINO, Rene PAREJA, Ranjit MANCHANDA, Jan KOSŤUN, Ricardo dos REIS, Mehmet Mutlu MEYDANLI, Diego ODETTO, Rene LAKY, Ignacio ZAPARDIEL, Vít WEINBERGER, Klára BENEŠOVÁ, Martina BORČINOVÁ, Fernando CARDENAS, Emelie WALLIN, Luigi Pedone ANCHORA, Huseyin AKILLI, Nadeem R ABU-RUSTUM, Salim Abraham BARQUET-MUÑOZ, Veronika JAVŮRKOVÁ, Daniela FISCHEROVÁ and Luc R C W van LONKHUIJZEN. Post-recurrence survival in patients with cervical cancer. Gynecologic Oncology. San Diego: Elsevier, vol. 164, No 2, p. 362-369. ISSN 0090-8258. doi:10.1016/j.ygyno.2021.12.018. 2022.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Post-recurrence survival in patients with cervical cancer
Authors CIBULA, David (203 Czech Republic, guarantor), Lukáš DOSTÁLEK (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Constantijne H MOM, Aldo LOPEZ, Henrik FALCONER, Giovanni SCAMBIA, Ali AYHAN, Sarah H KIM, David Isla ORTIZ, Jaroslav KLAT, Andreas OBERMAIR, Giampaolo Di MARTINO, Rene PAREJA, Ranjit MANCHANDA, Jan KOSŤUN, Ricardo dos REIS, Mehmet Mutlu MEYDANLI, Diego ODETTO, Rene LAKY, Ignacio ZAPARDIEL, Vít WEINBERGER (203 Czech Republic, belonging to the institution), Klára BENEŠOVÁ (203 Czech Republic, belonging to the institution), Martina BORČINOVÁ (203 Czech Republic), Fernando CARDENAS, Emelie WALLIN, Luigi Pedone ANCHORA, Huseyin AKILLI, Nadeem R ABU-RUSTUM, Salim Abraham BARQUET-MUÑOZ, Veronika JAVŮRKOVÁ (203 Czech Republic), Daniela FISCHEROVÁ (203 Czech Republic) and Luc R C W van LONKHUIJZEN.
Edition Gynecologic Oncology, San Diego, Elsevier, 2022, 0090-8258.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30214 Obstetrics and gynaecology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.700
RIV identification code RIV/00216224:14110/22:00125157
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.ygyno.2021.12.018
UT WoS 000789325700017
Keywords in English Early-stage cervical cancer; Recurrence; Post-recurrence disease-specific survival; Prognosis; Multivariable model; Risk profile
Tags 14110411, 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 28/6/2022 14:09.
Abstract
Background Up to 26% of patients with early-stage cervical cancer experience relapse after primary surgery. However, little is known about which factors influence prognosis following disease recurrence. Therefore, our aims were to determine post-recurrence disease-specific survival (PR-DSS) and to identify respective prognostic factors for PR-DSS. Methods Data from 528 patients with early-stage cervical cancer who relapsed after primary surgery performed between 2007 and 2016 were obtained from the SCANN study (Surveillance in Cervical CANcer). Factors related to the primary disease and recurrence were combined in a multivariable Cox proportional hazards model to predict PR-DSS. Results The 5-year PR-DSS was 39.1% (95% confidence interval [CI] 22.7%–44.5%), median disease-free interval between primary surgery and recurrence (DFI1) was 1.5 years, and median survival after recurrence was 2.5 years. Six significant variables were identified in the multivariable analysis and were used to construct the prognostic model. Two were related to primary treatment (largest tumour size and lymphovascular space invasion) and four to recurrence (DFI1, age at recurrence, presence of symptoms, and recurrence type). The C-statistic after 10-fold cross-validation of prognostic model reached 0.701 (95% CI 0.675–0.727). Three risk-groups with significantly differing prognoses were identified, with 5-year PR-DSS rates of 81.8%, 44.6%, and 12.7%. Conclusions We developed the robust model of PR-DSS to stratify patients with relapsed cervical cancer according to risk profiles using six routinely recorded prognostic markers. The model can be utilised in clinical practice to aid decision-making on the strategy of recurrence management, and to better inform the patients.
PrintDisplayed: 19/4/2024 05:11